Organic compounds -- part of the class 532-570 series – Organic compounds – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-11
2005-01-11
McKane, Joseph K. (Department: 1626)
Organic compounds -- part of the class 532-570 series
Organic compounds
Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
active
06841684
ABSTRACT:
Methods and compounds for the treatment of conditions including pain, particularly chronic pain, glaucoma or elevated intraocular pressure with reduced cardiovascular or sedative side effects. Also included are methods of making and using such compounds.
REFERENCES:
patent: 4443466 (1984-04-01), Karjalainen et al.
patent: 4496572 (1985-01-01), Cross et al.
patent: 4540705 (1985-09-01), Bailey
patent: RE32400 (1987-04-01), Karjalainen et al.
patent: 5021416 (1991-06-01), Gluchowski
patent: 5034406 (1991-07-01), Gluchowski
patent: 5066664 (1991-11-01), Gluchowski
patent: 5077292 (1991-12-01), Gluchowski
patent: 5091528 (1992-02-01), Gluchowski
patent: 5112822 (1992-05-01), Gluchowski
patent: 5130441 (1992-07-01), Gluchowski
patent: 5151440 (1992-09-01), Gluchowski
patent: 5151526 (1992-09-01), Hsu et al.
patent: 5180721 (1993-01-01), Burke et al.
patent: 5198442 (1993-03-01), Gluchowski
patent: 5215991 (1993-06-01), Burke et al.
patent: 5231096 (1993-07-01), Gluchowski
patent: 5552403 (1996-09-01), Burke et al.
patent: 5561132 (1996-10-01), Burke et al.
patent: 5580892 (1996-12-01), Garst et al.
patent: 5621113 (1997-04-01), Boyd et al.
patent: 5663189 (1997-09-01), Maurer et al.
patent: 5750720 (1998-05-01), Boyd et al.
patent: 0 194 984 (1986-09-01), None
patent: 0 304 910 (1989-03-01), None
patent: 1242571 (1989-09-01), None
patent: 4267130 (1992-09-01), None
patent: WO 9407866 (1994-04-01), None
patent: WO 9516449 (1995-06-01), None
patent: WO 9519968 (1995-07-01), None
patent: WO 9601813 (1996-01-01), None
patent: WO 9703079 (1997-01-01), None
patent: WO 9712874 (1997-04-01), None
patent: WO 9715302 (1997-05-01), None
patent: WO 9731636 (1997-09-01), None
patent: WO 9735858 (1997-10-01), None
Bylund et al, 1994, Pharmacol. Rev.46, pp. 121-136, “International Union of Pharmacology Nomenclature of Adrenoceptors”.
Shimizu et al, 1969, J. Neurochem.16, pp. 1609-1619, “A Radioisotopic Method For Measuring The Formation of Adenosine 3′, 5′-Cyclic Monophosphate in Incubated Slices of Brain”.
Messier et al, 1995, Pharmacol. Toxicol.76, pp. 308-311, “High Throughput Assays of Cloned Adrenergic, Muscarinic, Neurokinin, and Neurotrophin Receptors in Living Mammalian Cells”.
Neve et al, 1992, J. Biol. Chem.267, pp. 25748-25753, “Dopamine D2 Receptor Stimulation of Na+/H+Exchange Assessed by Quantification of Extracellular Acidification”.
Williams et al, 1990, J. Auton. Pharmacol, 10, 247, pp. 109-118, “α2-adrenceptor antisecretory responses in the rat jejunum”.
Fondacaro et al, 1988, vol. 247, No. 2, pp. 481-486, “The Journal of Pharmacology and Experimental Therapeutics”.
White et al, 1975, Communications/Synthesis, pp. 602-603, “A Convenient Procedure for the Preparation of 2-endo-Hydroxy-cis-bicyclo [3.3.0]octane”.
Conklin et al, Nature, 1993, vol. 363, pp. 274-276, “Substitution of three amino acids switches receptor specifity of Gqα to that of G1α”.
Schaaf et al, J. Med. Chem. 1983, vol. 26, pp. 328-334, “Structure-Activity Studies of Configurationally Rigid Arylprostaglandins”.
Kihara et al, “Preparation of imidazole derivatives as drugs”, 6001 Chemical Abstracts, Columbus, Ohio, U.S. vol. 112 (Apr. 9, 1996), No. 16, XP-002098179.
Zhang et al, “Medetomidine Analogs as α2-Adrenergic Ligands. 3. Synthesis annd Biological Evaluation of a New Series of Medetomidine Analogs and Their Potential Binding Interactions with α2-Adrenoceptors Involving a ‘Methyl Pocket’”, J. Med. Chemc. 1997, 40. pp. 3014-3024.
Burke James A.
Chow Ken
Garst Michael E.
Gil Daniel W.
Gomez Dario G.
Allergan Inc.
Anderson Rebecca
Baran Robert J.
Fisher Carlos A.
McKane Joseph K.
LandOfFree
Imidiazoles having reduced side effects does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Imidiazoles having reduced side effects, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Imidiazoles having reduced side effects will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3435203